Scientific Sessions 2024  /  Jardiance® (empagliflozin) tablets: Expert Perspectives on Clinical Trial Data and Approved Indications  /  Jardiance Empagliflozin tablets: Expert Perspectives on Clinical Trial Data and Approved Indications
Logo

American Heart Association

  2
  0

Final ID:

Jardiance Empagliflozin tablets: Expert Perspectives on Clinical Trial Data and Approved Indications

  • Butler, Javed  ( UMMC , Jackson , Mississippi , United States )
    • Author Disclosures:
    Javed Butler: DO have relevant financial relationships ; Consultant:Abbott, American Regent, Amgen, Applied Therapeutic,:Active (exists now) ; Speaker:Novartis, Boehringer Ingelheim-Lilly, Astra Zeneca, Impulse Dynamics, Vifor:Active (exists now) ; Consultant:Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vifor, and Zoll:Active (exists now) ; Consultant:Roche, Salamandra, Sanofi, SC Pharma, Secretome,:Active (exists now) ; Consultant:Pharmain, Pfize, Prolaio, Regeneron, Renibus,:Active (exists now) ; Consultant:Novartis, Novo Nordisk, Pfizer, Pharmacosmos,:Active (exists now) ; Consultant:Janssen, Medtronics, Merck, Occlutech, Owkin,:Active (exists now) ; Consultant:Inventiva, Ionis, Lexicon, Lilly, LivaNova,:Active (exists now) ; Consultant:Innolife, Impulse Dynamics, Imbria,:Active (exists now) ; Consultant:Faraday, Foundry, G3P,:Active (exists now) ; Consultant:Daxor, Edwards, Element Science,:Active (exists now) ; Consultant:Cardiorem, CSL Bearing, CVRx, Cytokinetics:Active (exists now) ; Consultant:Bristol Myers Squibb, Cardiac Dimension, Cardiocell, Cardior,:Active (exists now) ; Consultant:Bayer, Boehringer Ingelheim, Boston Scientific,:Active (exists now) ; Consultant:AskBio, Astellas, AstraZeneca,:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Jardiance® (empagliflozin) tablets: Expert Perspectives on Clinical Trial Data and Approved Indications

Saturday, 11/16/2024 , 01:45PM - 02:30PM

Learning Studio

More abstracts from these authors:
QCOR Community: How to Engage and Succeed

Butler Javed

Are incretin analogues the next STEP for HFpEF management in obesity?

Kosiborod Mikhail, Butler Javed

You have to be authorized to contact abstract author. Please, Login
Not Available